Recurrent Wilms Tumor and Other Childhood Kidney Tumors
13
0
0
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (13)
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Gene Expression Profiles to Categorize Wilms Tumors
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas